Phase 1, Randomized, Double-Blind, Pharmacokinetic and Glucodynamic, 6-Way Crossover Study of Subcutaneously Administered Insulin Analogs With Recombinant Human Hyaluronidase (rHuPH20) Compared to Insulin Analogs Alone in Healthy Volunteers.

Trial Profile

Phase 1, Randomized, Double-Blind, Pharmacokinetic and Glucodynamic, 6-Way Crossover Study of Subcutaneously Administered Insulin Analogs With Recombinant Human Hyaluronidase (rHuPH20) Compared to Insulin Analogs Alone in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2012

At a glance

  • Drugs Hyaluronidase (Primary) ; Insulin aspart (Primary) ; Insulin glulisine (Primary) ; Insulin lispro (Primary)
  • Indications Diabetes mellitus
  • Focus Pharmacokinetics
  • Most Recent Events

    • 24 Sep 2010 Results were reported at the 46th Annual Meeting of the European Association for the Study of Diabetes.
    • 28 Jun 2010 Results have been presented at the American Diabetes Association 70th Scientific Sessions, according to a Halozyme Therapeutics media release.
    • 22 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top